Shots:

• Eli Lilly initiates P-III BLAZE-2 study assessing LY-CoV555 to prevent SARS-CoV-2 infection and COVID-19 in residents and staff at long-term care facilities in the US (skilled nursing facilities- commonly referred to as nursing homes- and assisted living facilities)
• The company will enroll up to ~2400 patients and test whether a single dose of LY-CoV555 reduces the rate of SARS-CoV-2 infection @4wks. as well as complications of COVID-19 @8wks.
• LY-CoV555 is a potent- neutralizing IgG1 mAb- directed against the spike protein of SARS-CoV-2. The therapy emerges from the collaboration b/w Lilly and AbCellera to create Ab therapies for the prevention & treatment of COVID-19

­ Ref: Eli Lilly | Image: Eli Lilly